Alchemia banks on 2010

By Dylan Bushell-Embling
Thursday, 02 October, 2008

Alchemia [ASX: ACL] has recorded an $11 million loss for the financial year but reports a healthy cash reserve of $15.3 million.

Equity increased from around $87 million to $102 million.

The company expects to go into profit in 2010. Its generic fondaparinux, a copy of GSK’s Arixta, for venous thromboembolism, is scheduled for market launch in the US next year through its partner Dr Reddy’s.

Proposed Australian trial eyes up blood testing for Alzheimer's

Utilising networks of GPs across three states, a large-scale study intends on combining digital...

Applications open for $300K pandemic therapeutics fellowships

Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...

CTA granted for CAR-T cell therapy for multiple myeloma

The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...

Content from other channels on our network

What can food manufacturers learn from viral food trends?

Cargill expands its edible oil facility in Malaysia

The mathematics of fish freshness

Mitigating unseen losses in large food packs

Perfect Automation and Omori have joined forces with packaging solutions

National Pain Alliance launched to advocate for chronic pain

Sexual misconduct findings added to public register under "landmark reforms"

Australia invests further $14.6 million in national allergy research

Can seasonal influenza vaccination prime the immune system for future strains?

"Targeted supports" launched for former patients of Simon Gordon

Leafy greens identified as potential metal mining tools

Smart monitoring helps tram network cut water use by 70%

NSW closes EV gaps in regional areas

Call for 10c increase on container return schemes

Water transition key at Global Water Summit 2026